mavacamten | sciencenewsnet.in

Breaking News

Daniel B.F. Saris, MD, PhD, Receives the First Arnold I. Caplan Award for Distinguished Research in Orthobiologics

Wildfire smoke can carry toxins hundreds of kilometres, depositing grime on urban structures, surfaces: research

Los Alamos National Laboratory partners with OpenAI to advance national security

Friedman School Receives Historic $10 Million Gift for Financial Aid

Astronomers Detect Missing Ingredient in Cooking Up Stars

Researchers examine economic impacts of aquatic dead zones

UA Little Rock Awarded $750,000 Cybersecurity Training Grant

Happiness expert available: Case Western Reserve University researcher gives tips for how to build resilience, motivation and well-being in a time of crisis

MyOme and Novi Health Collaborate to Bring Whole Genome Testing to Employer Health Programs

Grossman wins 2025 Transatlantic Alliance Award in Endocrinology

30 Jan, 2025

Heart Experts Available to Discuss Approval of New Heart Drug

April 29, 2022 sarah JonasFeature

Today, the Food and Drug Administration (FDA) announced the approval of mavacamten, a new drug shown to provide relief to obstructive hypertrophic cardiomyopathy patients experiencing shortness of breath.